Fulcrum Therapeutics discontinued its experimental sickle-cell disease drug program after the U.S. Food and Drug Administration raised concerns about cancer risks.

The decision effectively ends the company's primary development effort and triggers a massive reduction in force, threatening the firm's operational viability.

The company said it discontinued the drug, known as pociredir, on June 2, 2024 [4]. According to the company, the FDA's concerns regarding potential cancer risks meant there was no longer a viable regulatory path forward for the product [2].

Following the announcement, the company's share price plummeted. Reports on the magnitude of the drop vary, with some sources stating shares fell about 50% [2], while others reported a decline of 54% [1].

In response to the loss of its lead program, Fulcrum Therapeutics plans to fire about 85% of its workforce [3]. The company is headquartered in Boston, Massachusetts, while the FDA operates from Silver Spring, Maryland [1].

This sudden collapse of the pociredir program removes the central asset from the company's portfolio. The scale of the layoffs suggests the firm is pivoting away from its previous business model or preparing for a significant downsizing to preserve remaining capital.

“the FDA's concerns regarding potential cancer risks meant there was no longer a viable regulatory path forward”

The failure of pociredir highlights the high-risk nature of biotech development, where a single regulatory hurdle regarding safety—specifically cancer risk—can instantly erase the value of a company's primary asset. By firing the vast majority of its staff, Fulcrum is acknowledging that it cannot sustain its current operations without its lead candidate, leaving the company in a precarious financial position as it seeks a new direction.